Age: 57
“I think it’s impossible to overestimate the impact that improved sleep quality has on wellbeing. This lady was struggling to function, her life ruled by night sweats and hot flushes occurring day and night. She felt exhausted. VEOZA reduced the frequency of VMS, but had a particularly beneficial impact on symptoms during the night, allowing her sleep, energy levels and brain function to recover. She was extremely averse to HRT and so relieved to find an effective treatment she could have. She still experiences good and not so good days but the improvement in her sleep quality has enabled normal functioning. My patient is relieved to have found a suitable treatment for her”.
VEOZA is not recommended in patients with severe renal impairment or with end-stage renal disease.
^Oxybutynin is not licensed for vasomotor symptoms associated with menopause and therefore this treatment would be off-label.
HRT, hormone replacement therapy
REFERENCES: 1. VEOZA Summary of Product Characteristics. 2. Data on file Data on File: ref 40499
Adverse events should be reported. For Ireland, Healthcare professionals are asked to report any suspected adverse reactions via: HPRA Pharmacovigilance, Website: www.hpra.ie or Astellas Pharma Co. Ltd. Tel:+353 1 467 1555, E-mail: irishdrugsafety@astellas.com.
MAT-IE-VEO-2025-00074 January 2026